Abramson Cancer Center at Penn Medicine: clinical-trial pipeline
Abramson Cancer Center at Penn Medicine is the sponsor of 457 clinical trials in ClinicalTrials.gov and the EU CTIS portal; 134 are not yet finished and 3 were first posted in the last 90 days. Source: Arcadium Data, data as of .
Trials by phase
| Phase | Trials |
|---|---|
| Not applicable | 257 |
| Phase 1 | 73 |
| Phase 2 | 70 |
| Phase 1/2 | 30 |
| Early phase 1 | 23 |
| Phase 3 | 2 |
| Phase 4 | 2 |
Trials by status
| Status | Trials |
|---|---|
| Completed | 249 |
| Recruiting | 77 |
| Active, not recruiting | 50 |
| Terminated | 46 |
| Withdrawn or not authorised | 27 |
| Not yet recruiting | 7 |
| Unknown | 1 |
Condition areas
| Area | Trials |
|---|---|
| Oncology | 398 |
| Gastroenterology and liver | 48 |
| Nephrology and urology | 41 |
| Women's health and obstetrics | 30 |
| Cardiovascular | 16 |
| Infectious disease and vaccines | 12 |
| Rare and genetic diseases | 11 |
| Dermatology | 10 |
| Immunology and rheumatology | 9 |
| Metabolic and endocrine (diabetes, obesity) | 9 |
| Haematology | 4 |
| Musculoskeletal | 3 |
Countries
| Country | Trials |
|---|---|
| United States | 441 |
| Canada | 3 |
| Botswana | 2 |
| Argentina | 1 |
| Germany | 1 |
| India | 1 |
| Italy | 1 |
Latest changes
| Day | Change | Trial |
|---|---|---|
| 2026-09-22 | New trial posted | Saruparib in HRDsig+ Solid Tumors |
| 2026-09-08 | New trial posted | DNP-MRSI of HCC Metabolism to Predict Therapeutic Response |
| 2026-09-01 | New trial posted | Prognostic Biomarkers for Patients With Human Papillomavirus (HPV) Positive Oropharyngeal… |
Open trials
The 25 most recently changed open trials.
| Registry id | Title | Phase | Status | Countries |
|---|---|---|---|---|
| NCT05496036 | Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma | Phase 2 | Recruiting | United States |
| NCT06586255 | Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer | Phase 1 | Recruiting | United States |
| NCT06056063 | Project Looking-Glass Evaluation | Not applicable | Active, not recruiting | United States |
| NCT07040891 | A Pilot Trial of "Just ASK™" to Increase Discussions About Breast Cancer Clinical Trials | Not applicable | Recruiting | United States |
| NCT05952141 | Strategies to Close the Gap From Cervical Cancer Diagnosis to Treatment in Botswana | Not applicable | Recruiting | Botswana, United States |
| NCT01577251 | The Radiation Oncology Registry and Biosample Repository | Not applicable | Recruiting | United States |
| NCT05758688 | PROton Therapy for Post Surgical Treatment of GYNecologic Cancer | Phase 2 | Recruiting | United States |
| NCT05279027 | Zr89 + PET Companion Trial | Early phase 1 | Active, not recruiting | United States |
| NCT05086497 | WBSI Guided Personalized Delivery of TTFields | Not applicable | Recruiting | United States |
| NCT07471958 | Implementation of eHealth Delivery Alternatives for Cancer Genetic Testing for Hereditary Cancer (eREACH3) | Not applicable | Recruiting | United States |
| NCT06870617 | Practical Geriatric Assessment (PGA) Implementation Strategies and Correlative Evaluations (PACE-70) | Not applicable | Active, not recruiting | United States |
| NCT04347161 | Implementation Strategies for Monitoring Adherence in Real Time | Not applicable | Active, not recruiting | United States |
| NCT04119713 | Autoimmunity After Checkpoint Blockade | Not applicable | Recruiting | United States |
| NCT05743049 | Collection of Circulating Biomarkers in Pancreatic Cancer | Not applicable | Recruiting | United States |
| NCT03646617 | Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma | Phase 2 | Active, not recruiting | United States |
| NCT07230795 | AI-informed Colorectal Cancer (CRC) Screening Navigation vs. Standard of Care Among Screening-naive Penn Medi… | Not applicable | Recruiting | United States |
| NCT04854304 | Abbreviate or FAST Breast MRI for Supplemental Breast Cancer Screening for Black Women at Average Risk and De… | Not applicable | Active, not recruiting | United States |
| NCT05396612 | Role of the Immune Environment in Response to Therapy in Breast Cancer | Not applicable | Recruiting | United States |
| NCT03863457 | [18F] F-GLN by PET/CT in Breast Cancer | Phase 1 | Recruiting | United States |
| NCT07658768 | Pilot Study of TumorGlow for Intraoperative Molecular Imaging of Sarcoma Metastases to the Lungs in Pediatric… | Early phase 1 | Not yet recruiting | |
| NCT06089954 | Penn Medicine Biobank Return of Results Program | Not applicable | Active, not recruiting | United States |
| NCT03760575 | Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (M… | Phase 1 | Recruiting | United States |
| NCT06610344 | BHB & CAR-T for Lymphomas | Not applicable | Recruiting | United States |
| NCT06436248 | Polygenic Risk Scores and Multi-cancer Early Detection for Ovarian Cancer | Not applicable | Active, not recruiting | United States |
| NCT04332367 | Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance | Phase 2 | Recruiting | United States |
All sponsors: clinical-trial pipeline by sponsor.
Track a sponsor's pipeline
The API returns the same trials by sponsor website, phase, status, condition and country with a change feed, joined to hiring and public contract awards. Try it without a key on one sponsor.
Sources: ClinicalTrials.gov (U.S. National Library of Medicine, public domain) and the EU Clinical Trials Information System public portal (European Medicines Agency), data as of 2026-10-25. A trial that one register cites in the other is shown once. Organisation-level data only: investigators, contact persons and site names are not stored, and a sponsor that could be a private person is withheld. Sponsor-to-website matches are made by name and can be wrong; check the register before relying on a record. Independent of the NLM, NIH and EMA.
Cite as: Arcadium Data, "Abramson Cancer Center at Penn Medicine clinical trials: 134 open, 2 in phase 3", https://arcadiumdata.io/clinical-trials/sponsor/abramson-cancer-center-at-penn-medicine/, data as of 2026-10-25.